Form 4: Bolt Biotherapeutics Executive Acquires Shares and Stock Options

Sarah Nemec, Senior VP of Finance and PAO at Bolt Biotherapeutics, reports acquiring shares through the Employee Stock Purchase Plan and stock options.

Summary

• Sarah Nemec, a Senior VP at Bolt Biotherapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On December 16, 2024, she acquired 2,500 shares of common stock at $0.4965 per share, increasing her direct holdings to 16,633 shares.
• On June 6, 2024, she acquired 2,500 shares of common stock at $0.6374 per share, increasing her direct holdings to 13,863 shares.
• On May 1, 2025, she was granted stock options for 226,000 shares with an exercise price of $0.351, vesting monthly starting January 1, 2025, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a routine disclosure of insider transactions. The acquisition of shares and granting of options are mildly positive signals.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates confidence in the company's future.
• The granting of stock options incentivizes the executive to remain with the company and contribute to its success.

Future Outlook

The vesting of stock options is contingent upon the reporting person's continuous service to the issuer.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's sentiment towards the company's prospects.

Stakeholder Impact

• Shareholders may view insider transactions as a signal of management's confidence in the company.
• Employees may be motivated by the fact that executives are also invested in the company's success.

Key Dates

Keywords

Form 4, Bolt Biotherapeutics, Sarah Nemec, stock options, share acquisition, beneficial ownership, insider trading